Teva Pharmaceutical Industries (TEVA) has emerged as a focal point for short sellers, with the latest FINRA short interest report for the September 15, 2026, settlement period showing a more than tenfold increase in short positions. While the data is approximately 18 days old, the magnitude of the increase is notable among the 2,809 companies tracked. This surge in open short interest suggests a significant shift in institutional positioning. Investors should cross-reference this stale FINRA data with real-time borrow fee trends to determine if the bearish sentiment has persisted or intensified in the weeks following the settlement date.
Signal data sourced from StockTitan. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.